Doc. 519

Dockets.Justia.com

Genentech, Inc. et al v. Sanofi-Aventis Deutschland GMBH et al

1		
	QUINN EMANUEL URQUHART &	FOLEY HOAG LLP
2	SULLIVAN, LLP	Donald R. Ware (pro hac vice)
	Charles K. Verhoeven (Bar No. 170151)	dware@foleyhoag.com
3	charlesverhoeven@quinnemanuel.com	Claire Laporte (pro hac vice)
	50 California Street, 22nd Floor	claporte@foleyhoag.com
4	San Francisco, California 94111	Jeremy A. Younkin
_	Telephone: (415) 875-6600	•
5	Facsimile: (415) 875-6700	jyounkin@foleyhoag.com
6	Victoria E Marculia (Par No. 202602)	Seaport World Trade Center West
O	Victoria F. Maroulis (Bar No. 202603) victoriamaroulis@quinnemanuel.com	155 Seaport Boulevard
7	Gabriel S. Gross (Bar No. 254672)	Boston, MA 02210-2600
	gabegross@quinnemanuel.com	Telephone: (617) 832-1180
8	555 Twin Dolphin Drive, 5th Floor	Facsimile: (617) 832-7000
	Redwood Shores, California 94065-2139	
9	Telephone: (650) 801-5000	Attorneys for Defendant Biogen Idec Inc.
	Facsimile: (650) 801-5100	
10		HARVEY SISKIND LLP
	Attorneys for Defendant Genentech, Inc.	D. Peter Harvey (Bar No. 55712)
11	TOWNSEND TOWNSEND & CDEWLLD	pharvey@harveysiskind.com
12	TOWNSEND, TOWNSEND & CREW LLP	Naomi Jane Gray
12	James G. Gilliland (Bar No. 107988)	ngray@harveysiskind.com Raffi V. Zerounian (Bar No. 236388)
13	jggilliland@townsend.com	rzerounian@harveysiskind.com
10	David J. Tsai (Bar No. 244479)	Four Embarcadero Center, 39th Floor
14	djtsai@townsend.co	San Francisco, California 94111
	Two Embarcadero Center, Eighth Floor	Telephone: (415) 354-0100
15	San Francisco, CA 94111	Facsimile: (415) 391-7124
1.	Telephone: (415) 576-0200	
16	Facsimile: (415) 576-0300	FITZPATRICK, CELLA, HARPER &
17		SCINTO William E. Salandar (admitted are has vise)
1 /	Anne M. Rogaski (Bar No. 184754)	William E. Solander (admitted pro hac vice) wsolander@fchs.com
18	amrogaski@townsend.com	Dominick A. Conde (admitted pro hac vice)
	379 Lytton Avenue	dconde@fchs.com
19	Palo Alto, CA 94301	Peter D. Shapiro (admitted pro hac vice)
	Telephone: (650) 326-2400	pshapiro@fchs.com
20	Facsimile: (650) 326-2422	Joshua A. Davis (admitted pro hac vice)
2.1		jdavis@fchs.com
21		1290 Avenue of the Americas
22		New York, New York 10104 Telephone: 212-218-2100
		Facsimile: 212-218-2200
23		1 desimile. 212 210 2200
		Attorneys for Plaintiff Sanofi-Aventis
24		Deutschland GmbH
25		
26		
26		
27		
- '		
28		

Pursuant to Civil Local Rules 6-1 and 6-2, Plaintiff Sanofi-Aventis Deutschland GmbH ("Sanofi") and Defendants Genentech, Inc. ("Genentech") and Biogen Idec Inc. ("Biogen") respectfully request that the Court enter the following stipulation regarding the deadline for conducting ADR. The parties now AGREE AND STIPULATE to extend the deadline for the parties to conduct an ADR from October 31, 2010 to January 31, 2011.

## 1. Reason for the Request

In its Order Selecting ADR Process (D.N. 74), the Court directed the parties to conduct a private ADR session 60 days after the entry of the Claim Construction Order. The Court issued its Claim Construction Order on June 23, 2010. On August 4, the parties requested additional time to select an appropriate mediator for this dispute, extending the deadline to conduct ADR to October 31, 2010. The parties have agreed on a mediator, but due to the mediator's limited availability through the end of 2010, the mediation will be scheduled to occur in January 2011.

## 2. Prior Time Modifications

The time for Sanofi to answer or otherwise respond to the Complaint was previously extended. The briefing and hearing schedule for Motions to Dismiss for Lack of Jurisdiction brought by Sanofi and its former co-defendants was temporarily vacated. The briefing and hearing schedule for Genentech's Motion To Disqualify McDonnell Boehnen Hulbert and Berghoff LLP was extended by four weeks. The briefing and hearing schedule for Sanofi's Motion for Leave to Amend Its Pleadings and Infringement Contentions was previously extended by five weeks and then extended again by seven weeks. The Markman hearing and tutorial were previously continued by 45 days. The date for Plaintiff's oppositions to Defendants' motions for summary judgment was extended by approximately three weeks. The date for Defendants' replies to Plaintiff's summary judgment oppositions was extended by one week. A previous extension of time to conduct ADR is described above.

## 3. Effect of Requested Modification

The requested modification will have no effect on the rest of the schedule in this action. So Stipulated.

1	DATED 0 41 27 2010	HADVEY GIGKDID LLD	
2	DATED: October 27, 2010	HARVEY SISKIND LLP FITZPATRICK, CELLA, HARPER & SCINTO	
3			
4		By/s/	
5		William E. Solander Attorneys for Plaintiff	
6		Sanofi-Aventis Deutschland GmbH	
7			
8	DATED: October 27, 2010	QUINN EMANUEL URQUHART & SULLIVAN, LLP	
10			
11		By /s/ Victoria F. Maroulis	
12		Attorneys for Defendant Genentech, Inc.	
13			
14	DATED: October 27, 2010	TOWNSEND TOWNSEND AND CREW LLP	
15		FOLEY HOAG LLP	
16			
17		By/s/ Claire Laporte	
18		Attorneys for Defendant Biogen Idec Inc.	
19			
20		or DISTD:	
21	PURSUANT TO STIPULATION, IT IS SO ORDERED, STATES DIOTRICALED		
22			
23		Judge Susan Illston	
24	DATED: 11/01/10	Judge Guit	
25		The Honorable Queen Historia United States District Court Judge	
26		Office States District Court stage	
27			
28			

-3-